methylphenidate has been researched along with Psychotic Disorders in 46 studies
Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.
methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.
methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.
Psychotic Disorders: Disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations. (From DSM-IV, 1994)
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study estimated the risk of developing psychotic disorders by comparing children with ADHD to non-ADHD controls, and to examine whether methylphenidate (MPH) treatment influences the risks of psychotic disorders." | 7.81 | Attention-deficit/hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia spectrum disorders: A nationwide population-based study in Taiwan. ( Lee, SY; Lee, TL; Shyu, YC; Wang, LJ; Yang, CJ; Yang, KC; Yuan, SS, 2015) |
| "Although neuroleptics are the major treatment for schizophrenia, there are no effective measures to determine the appropriate or necessary length of neuroleptic maintenance." | 5.27 | Methylphenidate challenge as a predictor of relapse in schizophrenia. ( Brenner, R; Gadaleta, D; Kane, JM; Kinon, B; Lesser, MS; Lieberman, JA, 1984) |
| "To investigate the mood response of schizophrenic subjects to psychostimulant challenge, 29 neuroleptic-treated subjects (22 with schizophrenia and 7 with schizoaffective disorder) in clinical remission received two infusions, one with methylphenidate 0." | 5.07 | Mood responses of remitted schizophrenics to methylphenidate infusion. ( Alvir, J; Cooper, T; Lieberman, J; Mayerhoff, D; Robinson, D, 1991) |
| "Our aim was to summarize the efficacy and safety of atomoxetine, amphetamines, and methylphenidate in schizophrenia." | 5.01 | Systematic review and exploratory meta-analysis of the efficacy, safety, and biological effects of psychostimulants and atomoxetine in patients with schizophrenia or schizoaffective disorder. ( Carvalho, AF; Correll, CU; de Bartolomeis, A; Fornaro, M; Köhler, CA; Solmi, M; Stubbs, B; Toyoshima, K; Veronese, N, 2019) |
| " This article describes a series of cases in which clozapine provided adequate control of psychosis in women suffering schizophrenia-spectrum disorders." | 4.93 | Stimulants for impulsive violence in schizophrenia spectrum disordered women: a case series and brief review. ( Skoretz, P; Tang, C, 2016) |
| " Withdrawal of the narcolepsy treatment and initiation of haloperidol 1 mg/day (the only antipsychotic treatment she could tolerate) improved the delusions, hallucinations and dysphoria but worsened the narcolepsy symptoms." | 3.85 | Narcolepsy-cataplexy and psychosis: a case study. ( Arango-Lopez, C; Canellas-Dols, F; Delgado, C; Peraita-Adrados, R, 2017) |
| "This study estimated the risk of developing psychotic disorders by comparing children with ADHD to non-ADHD controls, and to examine whether methylphenidate (MPH) treatment influences the risks of psychotic disorders." | 3.81 | Attention-deficit/hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia spectrum disorders: A nationwide population-based study in Taiwan. ( Lee, SY; Lee, TL; Shyu, YC; Wang, LJ; Yang, CJ; Yang, KC; Yuan, SS, 2015) |
| "A second case of severe limb malformations was observed following maternal use of haloperidol early in the first trimester of pregnancy." | 3.65 | Limb malformations following maternal use of haloperidol. ( Heggeness, L; McCullar, FW, 1975) |
| "013), and similar side effect rates." | 1.72 | Stimulant treatment effectiveness, safety and risk for psychosis in individuals with 22q11.2 deletion syndrome. ( Basel, D; Eliez, S; Gothelf, D; Maeder, J; Mosheva, M; Schneider, M; Shani, S; Weinberger, R, 2022) |
| "Although neuroleptics are the major treatment for schizophrenia, there are no effective measures to determine the appropriate or necessary length of neuroleptic maintenance." | 1.27 | Methylphenidate challenge as a predictor of relapse in schizophrenia. ( Brenner, R; Gadaleta, D; Kane, JM; Kinon, B; Lesser, MS; Lieberman, JA, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 19 (41.30) | 18.7374 |
| 1990's | 10 (21.74) | 18.2507 |
| 2000's | 1 (2.17) | 29.6817 |
| 2010's | 9 (19.57) | 24.3611 |
| 2020's | 7 (15.22) | 2.80 |
| Authors | Studies |
|---|---|
| Gudbrandsdottir, RK | 1 |
| Sigurdsson, E | 1 |
| Ingimarsson, O | 1 |
| Kooij, JJS | 1 |
| Girgis, RR | 1 |
| Slifstein, M | 1 |
| Brucato, G | 1 |
| Kegeles, LS | 1 |
| Colibazzi, T | 1 |
| Lieberman, JA | 3 |
| Abi-Dargham, A | 1 |
| Zhand, N | 1 |
| Harvey, P | 1 |
| Osborne, R | 1 |
| Hatko, A | 1 |
| Stuyt, M | 1 |
| Labelle, A | 1 |
| Lancee, M | 1 |
| Maat, A | 1 |
| van Veelen, N | 1 |
| Roder, CH | 1 |
| Schellekens, AFA | 1 |
| Batalla, A | 1 |
| Basel, D | 1 |
| Mosheva, M | 1 |
| Maeder, J | 1 |
| Schneider, M | 1 |
| Shani, S | 1 |
| Weinberger, R | 1 |
| Eliez, S | 1 |
| Gothelf, D | 1 |
| Gering, A | 1 |
| Fourneret, P | 1 |
| Poulet, E | 1 |
| Geoffray, MM | 1 |
| Jurek, L | 1 |
| Canellas-Dols, F | 1 |
| Delgado, C | 1 |
| Arango-Lopez, C | 1 |
| Peraita-Adrados, R | 1 |
| Solmi, M | 1 |
| Fornaro, M | 1 |
| Toyoshima, K | 1 |
| Carvalho, AF | 1 |
| Köhler, CA | 1 |
| Veronese, N | 1 |
| Stubbs, B | 1 |
| de Bartolomeis, A | 1 |
| Correll, CU | 1 |
| Cortese, S | 1 |
| Hechtman, L | 1 |
| Shyu, YC | 1 |
| Yuan, SS | 1 |
| Lee, SY | 1 |
| Yang, CJ | 1 |
| Yang, KC | 1 |
| Lee, TL | 1 |
| Wang, LJ | 1 |
| Merrill, RM | 1 |
| Thygerson, SM | 1 |
| Palmer, CA | 1 |
| Skoretz, P | 1 |
| Tang, C | 1 |
| Blom, JD | 1 |
| Kooij, JJ | 1 |
| Vergouwen, T | 1 |
| Gorissen-Van Eenige, M | 1 |
| HOLT, EK | 3 |
| NISWANDER, GD | 3 |
| MORGAN, DR | 1 |
| SHEA, JG | 1 |
| SCHULTZ, JD | 1 |
| LEWIS, E | 1 |
| FAZEKAS, JF | 1 |
| WODRASKA, TW | 1 |
| SAUNDERS, JC | 1 |
| KLINE, NS | 1 |
| BARUCCI, M | 1 |
| MORI, F | 1 |
| DARVILL, FT | 1 |
| WOOLLEY, S | 1 |
| JOHNSEN, G | 1 |
| LEHMANN, HE | 1 |
| BAN, TA | 1 |
| Kishi, Y | 1 |
| Konishi, S | 1 |
| Koizumi, S | 1 |
| Kudo, Y | 1 |
| Kurosawa, H | 1 |
| Kathol, RG | 1 |
| Kane, JM | 1 |
| Gadaleta, D | 1 |
| Brenner, R | 1 |
| Lesser, MS | 1 |
| Kinon, B | 1 |
| Kleber, HD | 1 |
| Gawin, FH | 1 |
| Wilens, TE | 1 |
| Spencer, T | 1 |
| Biederman, J | 1 |
| Wozniak, J | 1 |
| Connor, D | 1 |
| Lieberman, J | 2 |
| Jody, D | 2 |
| Geisler, S | 1 |
| Alvir, J | 2 |
| Loebel, A | 1 |
| Szymanski, S | 1 |
| Woerner, M | 1 |
| Borenstein, M | 1 |
| Burke, M | 1 |
| Sebastian, CS | 1 |
| Alvir, JM | 1 |
| Ashtari, M | 1 |
| Levy, DL | 1 |
| Bogerts, B | 1 |
| Degreef, G | 1 |
| Mayerhoff, DI | 1 |
| Cooper, T | 2 |
| Miller, SC | 1 |
| Elman, I | 1 |
| Sigler, M | 1 |
| Kronenberg, J | 1 |
| Lindenmayer, JP | 1 |
| Doron, A | 1 |
| Mendlovic, S | 1 |
| Gaoni, B | 1 |
| Simeon, J | 1 |
| O'Malley, M | 1 |
| Tryphonas, H | 1 |
| Graham, D | 1 |
| Mastronardi, M | 1 |
| Simeon, S | 1 |
| Griffin, J | 1 |
| Huapaya, LV | 1 |
| Janowsky, DS | 2 |
| Davis, JM | 4 |
| Huey, L | 1 |
| Judd, LL | 1 |
| Renshaw, DC | 1 |
| Schain, RJ | 1 |
| McCullar, FW | 1 |
| Heggeness, L | 1 |
| Rosenberg, DR | 1 |
| Crowner, S | 1 |
| Thomas, C | 1 |
| Gourash, L | 1 |
| Sharma, RP | 2 |
| Javaid, JI | 2 |
| Pandey, GN | 2 |
| Janicak, PG | 1 |
| Robinson, D | 1 |
| Mayerhoff, D | 1 |
| Easton, M | 1 |
| Angrist, B | 1 |
| Gershon, S | 1 |
8 reviews available for methylphenidate and Psychotic Disorders
| Article | Year |
|---|---|
[ADHD during childhood and subsequent psychotic disorder: A link?]
Topics: Attention Deficit Disorder with Hyperactivity; Comorbidity; Humans; Infant, Newborn; Methylphenidate | 2021 |
Systematic review and exploratory meta-analysis of the efficacy, safety, and biological effects of psychostimulants and atomoxetine in patients with schizophrenia or schizoaffective disorder.
Topics: Amphetamines; Antipsychotic Agents; Atomoxetine Hydrochloride; Attention; Executive Function; Humans | 2019 |
Stimulants for impulsive violence in schizophrenia spectrum disordered women: a case series and brief review.
Topics: Adult; Antipsychotic Agents; Central Nervous System Stimulants; Clozapine; Drug Therapy, Combination | 2016 |
Schizophrenia and narcolepsy: a review with a case report.
Topics: Adult; Antipsychotic Agents; Cataplexy; Central Nervous System Stimulants; Comorbidity; Diagnosis, D | 2004 |
The spectrum of cocaine abuse and its treatment.
Topics: Ambulatory Care; Antidepressive Agents, Tricyclic; Behavior Therapy; Cocaine; Depressive Disorder; H | 1984 |
Minimal brain Dysfunction.
Topics: Attention Deficit Disorder with Hyperactivity; Brain Diseases; Cerebral Palsy; Child; Child, Prescho | 1975 |
Psychosis and idiopathic precocious puberty in two 7-year-old boys.
Topics: Attention Deficit Disorder with Hyperactivity; Body Height; Carbamazepine; Child; Developmental Disa | 1992 |
Dopamine and psychotic states: preliminary remarks.
Topics: Amphetamine; Animals; Apomorphine; Behavior, Animal; Carbon Radioisotopes; Cats; Cocaine; Dihydroxyp | 1974 |
5 trials available for methylphenidate and Psychotic Disorders
| Article | Year |
|---|---|
Characteristics of patients with schizophrenia successive to childhood attention deficit hyperactivity disorder (ADHD).
Topics: Adolescent; Adult; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Central Nerv | 1998 |
Behavioral and biochemical effects of methylphenidate in schizophrenic and nonschizophrenic patients.
Topics: Adult; Brain; Depressive Disorder; Double-Blind Method; Female; Growth Hormone; Homovanillic Acid; H | 1991 |
Mood responses of remitted schizophrenics to methylphenidate infusion.
Topics: Adolescent; Adult; Affect; Double-Blind Method; Female; Humans; Infusions, Intravenous; Male; Methyl | 1991 |
Pharmacological effects of methylphenidate on plasma homovanillic acid and growth hormone.
Topics: Adult; Affective Disorders, Psychotic; Blood Pressure; Brain; Double-Blind Method; Female; Growth Ho | 1990 |
Dopamine, psychomotor stimulants, and schizophrenia: effects of methylphenidate and the stereoisomers of amphetamine in schizophrenics.
Topics: Amphetamine; Behavior; Clinical Trials as Topic; Dextroamphetamine; Dopamine; Humans; Methylphenidat | 1974 |
33 other studies available for methylphenidate and Psychotic Disorders
| Article | Year |
|---|---|
[Methylphenidate-induced psychosis in a young adult with newly diagnosed ADHD: A case report].
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Iceland; M | 2023 |
[Risk of psychosis with treatment for ADHD].
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2020 |
Imaging synaptic dopamine availability in individuals at clinical high-risk for psychosis: a [
Topics: Dopamine; Humans; Methylphenidate; Positron-Emission Tomography; Psychotic Disorders; Receptors, Dop | 2021 |
Retrospective review of use of adjunctive psychostimulants in patients with schizophrenia.
Topics: Adjuvants, Pharmaceutic; Attention; Attention Deficit Disorder with Hyperactivity; Canada; Central N | 2021 |
Topics: Central Nervous System Stimulants; Humans; Methylphenidate; Psychotic Disorders | 2021 |
Stimulant treatment effectiveness, safety and risk for psychosis in individuals with 22q11.2 deletion syndrome.
Topics: Adolescent; Catechol O-Methyltransferase; Central Nervous System Stimulants; DiGeorge Syndrome; Huma | 2022 |
Narcolepsy-cataplexy and psychosis: a case study.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compound | 2017 |
Psychosis during Attention Deficit-Hyperactivity Disorder Treatment with Stimulants.
Topics: Amphetamine; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Human | 2019 |
ADHD medication treatment and risk of psychosis.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cohort | 2019 |
Attention-deficit/hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia spectrum disorders: A nationwide population-based study in Taiwan.
Topics: Adolescent; Age of Onset; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2015 |
Risk of Injury According to Attention Deficit Hyperactivity Disorder, Comorbid Mental Illness, and Medication Therapy.
Topics: Adolescent; Adult; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperacti | 2016 |
[ADD psychosis: treatment with antipsychotics and methylphenidate?].
Topics: Adult; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous System S | 2012 |
[Response to 'ADD psychosis: treatment with antipsychotics and methylphenidate?'].
Topics: Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulan | 2012 |
Combination reserpine-methylphenidylacetate in epileptics with psychosis.
Topics: Epilepsy; Methylphenidate; Psychotic Disorders; Reserpine | 1957 |
Combination reserpine-methylphenidylacetate in epileptics with psychosis.
Topics: Epilepsy; Methylphenidate; Psychotic Disorders; Reserpine | 1957 |
Combination reserpine-methylphenidylacetate in epileptics with psychosis.
Topics: Epilepsy; Methylphenidate; Psychotic Disorders; Reserpine | 1957 |
Combination reserpine-methylphenidylacetate in epileptics with psychosis.
Topics: Epilepsy; Methylphenidate; Psychotic Disorders; Reserpine | 1957 |
Largactil, ritalin and meratran in the treatment of endogenous psychotic depression.
Topics: Bipolar Disorder; Chlorpromazine; Depression; Depressive Disorder, Major; Methylphenidate; Piperidin | 1957 |
The clinical and cerebral action of promethazine and methylphenidate hydrochloride.
Topics: Counseling; Humans; Medical Records; Mental Disorders; Methylphenidate; Promethazine; Psychoses, Alc | 1958 |
Combined ritalin and serpasil therapy in chronic psychoses.
Topics: Mental Disorders; Methylphenidate; Psychosurgery; Psychotherapy; Psychotic Disorders; Reserpine | 1958 |
[Effects of reserpine combined with a psycho-analeptic drug on mental efficiency of the aged].
Topics: Aged; Arteriosclerosis; Central Nervous System Stimulants; Dementia; Mental Disorders; Methylphenida | 1957 |
Combination reserpine-methylphenidate in epileptics with psychosis; final report.
Topics: Epilepsy; Mental Disorders; Methylphenidate; Psychotic Disorders; Reserpine | 1958 |
Double blind evaluation of methylphenidate (ritalin) hydrochloride; its use in the management of institutionalized geriatric patients.
Topics: Dementia; Disease Management; Double-Blind Method; Humans; Mental Disorders; Methylphenidate; Patien | 1959 |
[CLINICAL ASPECTS OF MODEL PSYCHOSES].
Topics: Anorexia Nervosa; Convulsive Therapy; Hospitals, Psychiatric; Humans; Insulin; Lysergic Acid Diethyl | 1964 |
NOTES FROM THE LOG-BOOK OF A PSYCHOPHARMACOLOGICAL RESEARCH UNIT. II.
Topics: Antidepressive Agents; Books; Dextroamphetamine; Diazepam; Geriatrics; Humans; Mental Disorders; Met | 1964 |
Methylphenidate challenge as a predictor of relapse in schizophrenia.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Female; Humans; Infusions, Parenteral; Male; Methy | 1984 |
Combined pharmacotherapy: an emerging trend in pediatric psychopharmacology.
Topics: Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Benzodiazepines; Child Psychiatry; | 1995 |
Time course and biologic correlates of treatment response in first-episode schizophrenia.
Topics: Adult; Antipsychotic Agents; Biomarkers; Cohort Studies; Eye Movements; Female; Growth Hormone; Huma | 1993 |
Treatment of clozapine sedation.
Topics: Adult; Clozapine; Drug Therapy, Combination; Humans; Male; Methylphenidate; Psychotic Disorders; Sch | 1993 |
Brain morphology, dopamine, and eye-tracking abnormalities in first-episode schizophrenia. Prevalence and clinical correlates.
Topics: Adolescent; Adult; Apomorphine; Biomarkers; Brain; Cohort Studies; Dopamine; Eye Movements; Female; | 1993 |
Methylphenidate for clozapine sedation.
Topics: Clozapine; Disorders of Excessive Somnolence; Drug Monitoring; Humans; Male; Methylphenidate; Middle | 1996 |
Cromolyn DSG effects in hyperkinetic and psychotic children with allergies.
Topics: Adolescent; Adult; Child; Cromolyn Sodium; Dose-Response Relationship, Drug; Drug Evaluation; Humans | 1979 |
Seven cases of somnambulism induced by drugs.
Topics: Adult; Alcoholism; Amitriptyline; Chlorprothixene; Depression; Drug Therapy, Combination; Ethchlorvy | 1979 |
Methylphenidate and physostigmine as diagnostic tools.
Topics: Affective Symptoms; Humans; Methylphenidate; Physostigmine; Psychotic Disorders | 1978 |
Mentally retarded, hyperkinetic and psychotic.
Topics: Adult; Female; Humans; Hyperkinesis; Indoles; Intellectual Disability; Methylphenidate; Molindone; P | 1977 |
Limb malformations following maternal use of haloperidol.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Drug Therapy, Combination; Female; Fetus; Halo | 1975 |